New Hunter Syndrome Drug Receives FDA Approval
The drug Avlayah offers patients up to age 16 a new treatment that reaches the brain and body.
Updated on Oct. 21, 2026 in Allergies
In March 2026, the FDA granted accelerated approval for the drug Avlayah to treat patients up to age 16 with Hunter syndrome. This therapy is now available for those seeking to address both physical and neurological symptoms of the condition.
Why it matters
Previous enzyme replacement therapies have been the standard since 2006 but failed to cross the blood-brain barrier. Avlayah offers a new approach by reaching the brain, potentially addressing complications that prior treatments could not treat.
The FDA granted accelerated approval for Avlayah in March 2026 based on its ability to cross the blood-brain barrier in patients up to age 16. While this provides a new treatment pathway, clinical efficacy beyond initial findings remains under investigation.
The players
FDA
The federal agency responsible for evaluating the safety and effectiveness of new medical treatments.
Cole Stephens
A patient with Hunter syndrome who began receiving infusions of Avlayah in May 2026.
The details
Hunter syndrome occurs when patients lack the enzyme necessary to clear cellular waste. Avlayah functions as an enzyme replacement therapy that moves through the bloodstream and across the blood-brain barrier, preventing the harmful buildup of glycosaminoglycans throughout the body and brain. Unlike previous treatments, this infusion is designed to treat both systemic and neurological aspects of the disease.
Timeline
2006: Enzyme replacement therapy became the only approved treatment.
March 2026: The FDA granted accelerated approval for Avlayah.
May 2026: Cole Stephens received his first infusion of Avlayah.
Health Landscape
This development represents a shift from treatments that addressed only physical symptoms toward therapies capable of targeting neurological manifestations. It expands the available options for pediatric patients who have relied on 2006-era standards for nearly two decades.
Families of patients under age 16 with Hunter syndrome may wish to discuss with their specialist whether this new infusion is an appropriate option for their specific care plan. Since the treatment is a weekly intravenous infusion, patients should consult their clinical team about logistics and future possibilities for home-based care.
The takeaway
Avlayah provides a new avenue for treating both the physical and neurological symptoms of Hunter syndrome in children. Families should maintain a conversation with their primary care team or specialist to track new developments in treatment delivery and eligibility criteria.
Further reading
For more information on managing rare genetic conditions, visit our Allergies section.
